China Overhauls ADR Reporting Regulations That Place Additional Responsibility On Drug Makers
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA released new guidelines for adverse drug reaction reporting May 24 that will dramatically increase the postmarket reporting responsibilities of manufacturers, distributors and hospitals
You may also be interested in...
China Looks To Tighten Requirements On Adverse Event Reporting
Draft guidelines from SFDA would impact both foreign and domestic pharmaceutical manufacturers.
China's New ADR Reporting Regulations Still Leave Uncertainty For Clinical Requirements
SHANGHAI - China implemented revised guidelines for adverse drug reaction reporting July 1 to increase postmarket reporting responsibilities of manufacturers, distributors and hospitals. However, the regulations need to be improved to provide specific responsibilities and qualifications for company-appointed ADR monitors as well as how to deal with adverse drug reactions during clinical research, according to a clinical expert
China's New ADR Reporting Regulations Still Leave Uncertainty For Clinical Requirements
SHANGHAI - China implemented revised guidelines for adverse drug reaction reporting July 1 to increase postmarket reporting responsibilities of manufacturers, distributors and hospitals. However, the regulations need to be improved to provide specific responsibilities and qualifications for company-appointed ADR monitors as well as how to deal with adverse drug reactions during clinical research, according to a clinical expert